Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis-Reference-Cited by-同舟云学术

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

Published:2017-06-27 Issue:45 Volume:8 Page:79073-79086
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Palandri Francesca¹,Palumbo Giuseppe Alberto²,Bonifacio Massimiliano³,Tiribelli Mario⁴,Benevolo Giulia⁵,Martino Bruno⁶,Abruzzese Elisabetta⁷,D’Adda Mariella⁸,Polverelli Nicola⁹,Bergamaschi Micaela¹⁰,Tieghi Alessia¹¹,Cavazzini Francesco¹²,Ibatici Adalberto¹³,Crugnola Monica¹⁴,Bosi Costanza¹⁵,Latagliata Roberto¹⁶,Di Veroli Ambra¹⁷,Scaffidi Luigi³,de Marchi Federico⁴,Cerqui Elisa⁸,Anaclerico Barbara¹⁸,De Matteis Giovanna¹⁹,Spinsanti Marco¹,Sabattini Elena¹,Catani Lucia¹,Aversa Franco¹⁴,Di Raimondo Francesco²,Vitolo Umberto⁵,Lemoli Roberto Massimo¹⁰,Fanin Renato⁴,Merli Francesco¹¹,Russo Domenico⁹,Cuneo Antonio¹²,Bacchi Reggiani Maria Letizia²⁰,Cavo Michele¹,Vianelli Nicola¹,Breccia Massimo¹⁶

Affiliation:

1. Institute of Hematology “L. and A. Seràgnoli”, Sant'Orsola-Malpighi University Hospital, Bologna, Italy

2. Division of Hematology, AOU 'Policlinico-V.Emanuele', Catania, Italy

3. Department of Hematology, University of Verona, Verona, Italy

4. Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

5. Division of Hematology, Città della Salute e della Scienza Hospital, Torino, Italy

6. Division of Hematology, Azienda Ospedaliera 'Bianchi Melacrino Morelli', Reggio Calabria, Italy

7. Division of Hematology, Ospedale S. Eugenio, Roma, Italy

8. Division of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy

9. Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy

10. Division of Hematology, IRCCS AOU San Martino-IST, Genova, Italy

11. Department of Hematology, A.O. Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy

12. Division of Hematology, University of Ferrara, Ferrara, Italy

13. Division of Hematology and Bone Marrow Transplant, IRCCS San Martino-IST, Genova, Italy

14. Division of Hematology, AOU of Parma, Parma, Italy

15. Department of Hematology and Bone Marrow Transplantation, A.O. of Piacenza, Italy

16. Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Italy

17. Division of Hematology, Policlinico Tor Vergata, Roma, Italy

18. Division of Hematology, Ospedale S. Giovanni, Roma, Italy

19. Department of Life and Reproduction Sciences, Section of Clinical Biochemistry, University of Verona, Verona, Italy

20. Division of Cardiology, University of Bologna, Bologna, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study;Oncohematology;2024-09-01

2. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study;Cancer;2024-07-30

4. Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives;Frontiers in Oncology;2024-07-24

5. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02